Real-World Multicenter Study of Rezvilutamide Plus Androgen Deprivation Therapy in Chinese Patients with High-Volume Metastatic Hormone-Sensitive Prostate Cancer

Shuang Peng¹Ruochen Zhang²Zijun Zou³Qichen Wei⁴Caixia Dai¹Jinfeng Wu²Liefu Ye²Yongbao Wei^2,5Li Huang^1*

• ¹The Second Xiangya Hospital of Central South University, Changsha, China
• ²Fuzhou University, Fuzhou, China
• ³Guizhou Provincial People's Hospital, Guiyang, China
• ⁴Gutian County Hospital, Ningde, China
• ⁵Fujian Provincial Hospital, Fuzhou, China

Background: Rezvilutamide combined with androgen deprivation therapy (ADT) has become a first-line standard regimen for high-volume metastatic hormone-sensitive prostate cancer (mHSPC), but real-world evidence from China remains limited. Methods: This was a multicenter, retrospective real-world cohort study enrolling high-volume mHSPC patients diagnosed and treated with rezvilutamide plus ADT at multiple tertiary hospitals in China from August 2023 to March 2025. Baseline demographics, tumor burden, treatment regimen, and follow-up data were collected. The primary endpoints were 3-month PSA responses (PSA50, PSA90, PSA ≤0.2 ng/mL), subgroup efficacy, and adverse event rates. Multivariable logistic regression was used to identify independent predictors for achieving PSA ≤0.2 ng/mL at 3 months. Efficacy and safety outcomes were compared with major randomized controlled trials (RCTs) and other real-world studies. Results: A total of 236 patients with high-volume mHSPC were enrolled, with a median age of 74.9 years. The rates of achieving PSA50, PSA90, and PSA ≤0.2 ng/mL at 3 months were 99.15%, 88.98%, and 39.41%, respectively. Subgroup analysis showed consistent efficacy across age, ECOG, and Gleason strata, with only lower baseline PSA predicting higher likelihood of undetectable PSA. Multivariable analysis further indicated that baseline PSA showed a trend toward being an independent predictor for achieving PSA ≤0.2 ng/mL (P=0.063)